Maria Gebre-Medhin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Gebre-Medhin has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Per Nilsson
Department of Clinical Sciences (Lund), Lund University, Lund, Sweden; Department of Hematology, Oncology & Radiation Physics, Skåne University Hospital, Lund, Sweden
5 shared publications - Björn Zackrisson
Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden
4 shared publications Gabriel Adrian
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden; Department of Clinical Sciences Lund, Division of Oncology, Skåne University Hospital, Lund University, Lund, Sweden
3 shared publications- Gabriel Adrian
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
3 shared publications Johan Reizenstein
Department of Oncology, Örebro University Hospital, Örebro, Sweden
3 shared publications- Johanna Sjövall
Department of ORL, Head and Neck Surgery, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences (Lund), Lund University, Lund, Sweden
3 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 222, 111688
Quality of life and cost-effectiveness of preoperative accelerated versus postoperative conventional radiotherapy for oral cavity cancer: Results from the randomised ARTSCAN 2 trial
- 10 July 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 222, 111688
Open AccessQuality of life and cost-effectiveness of preoperative accelerated versus postoperative conventional radiotherapy for oral cavity cancer: Results from the randomised ARTSCAN 2 trial
- Open Access
- 1 June 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101202
Radiotherapy with or without concurrent cetuximab in HPV-positive oropharyngeal squamous cell carcinoma – A pooled analysis from two ARTSCAN trials
- 1 June 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101202
Open AccessRadiotherapy with or without concurrent cetuximab in HPV-positive oropharyngeal squamous cell carcinoma – A pooled analysis from two ARTSCAN trials
- Open Access
- 30 May 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101205
Daily adaptive radiotherapy in head and neck squamous cell carcinoma can negatively impact organ at risk dosimetry
- 30 May 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101205
Open AccessDaily adaptive radiotherapy in head and neck squamous cell carcinoma can negatively impact organ at risk dosimetry
- Open Access
- 19 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111607
Artificial intelligence classification of spatial CD8 + T-cell distribution on computed tomography in oropharyngeal cancer
- 19 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111607
Open AccessArtificial intelligence classification of spatial CD8 + T-cell distribution on computed tomography in oropharyngeal cancer
- 3 February 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (3) , 686-691
Circulating Tumor DNA in Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Carcinoma—Are We Ready to Individualize Treatment?
- 3 February 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 124 (3) , 686-691
Circulating Tumor DNA in Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Carcinoma—Are We Ready to Individualize Treatment?
- Open Access
- 23 January 2026
- Published by Elsevier in Oral Oncology
- Vol. 174, 107863
Carcinoma of the parotid Gland: A Population-Based study of incidence and treatment outcomes in 1018 patients
- 23 January 2026
- Published by Elsevier in Oral Oncology
- Vol. 174, 107863
Open AccessCarcinoma of the parotid Gland: A Population-Based study of incidence and treatment outcomes in 1018 patients
- Open Access
- 19 June 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (3) , 681-690
Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer—Mature Results of the ARTSCAN III Trial
- 19 June 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (3) , 681-690
Open AccessChemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer—Mature Results of the ARTSCAN III Trial
- Open Access
- 28 June 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 186, 109773
Circulating tumour HPV16 DNA quantification – A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy
- 28 June 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 186, 109773
Open AccessCirculating tumour HPV16 DNA quantification – A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy
- Open Access
- 14 June 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-13
Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy
Background: The prescribed radiation dose to patients with oropharyngeal squamous cell carcinoma (OPSCC) is standardized, even if the prognosis for individual patients may differ. Easy-at-hand pre-treatment risk stratification methods are valuable to individualize therapy. In the current study we assessed the prognostic impact of primary tumor volume for p16-positive and p16-negative tumors and in relationship to other prognostic factors for outcome in patients with OPSCC treated with primary radiation therapy (RT). Methods: Five hundred twenty-three OPSCC patients with p16-status treated with primary RT (68.0 Gy to 73.1 Gy in 7 weeks, or 68.0 Gy in 4.5 weeks), with or without concurrent chemotherapy, within three prospective trials were included in the study. Local failure (LF), progression free survival (PFS) and overall survival (OS) in relationship to the size of the primary gross tumor volume (GTV-T) and other prognostic factors were investigated. Efficiency of intensified RT (RT with total dose 73.1 Gy or given within 4.5 weeks) was analyzed in relationship to tumor volume. Results: The volume of GTV-T and p16-status were found to be the strongest prognostic markers for LF, PFS and OS. For p16-positive tumors, an increase in tumor volume had a significantly higher negative prognostic impact compared with p16-negative tumors. Within a T-classification, patients with a smaller tumor, compared with a larger tumor, had a better prognosis. The importance of tumor volume remained after adjusting for nodal status, age, performance status, smoking status, sex, and hemoglobin-level. The adjusted hazard ratio for OS per cm3 increase in tumor volume was 2.3% (95% CI 0–4.9) for p16-positive and 1.3% (95% 0.3–2.2) for p16-negative. Exploratory analyses suggested that intensified RT could mitigate the negative impact of a large tumor volume. Conclusions: Outcome for patients with OPSCC treated with RT is largely determined by tumor volume, even when adjusting for other established prognostic factors. Tumor volume is significantly more influential for patients with p16-positive tumors. Patients with large tumor volumes might benefit by intensified RT to improve survival.
- 14 June 2022
- Published by Springer Nature in Radiation Oncology
- Vol. 17 (1) , 1-13
Open AccessPrimary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy
Background: The prescribed radiation dose to patients with oropharyngeal squamous cell carcinoma (OPSCC) is standardized, even if the prognosis for individual patients may differ. Easy-at-hand pre-treatment risk stratification methods are valuable to individualize therapy. In the current study we assessed the prognostic impact of primary tumor volume for p16-positive and p16-negative tumors and in relationship to other prognostic factors for outcome in patients with OPSCC treated with primary radiation therapy (RT). Methods: Five hundred twenty-three OPSCC patients with p16-status treated with primary RT (68.0 Gy to 73.1 Gy in 7 weeks, or 68.0 Gy in 4.5 weeks), with or without concurrent chemotherapy, within three prospective trials were included in the study. Local failure (LF), progression free survival (PFS) and overall survival (OS) in relationship to the size of the primary gross tumor volume (GTV-T) and other prognostic factors were investigated. Efficiency of intensified RT (RT with total dose 73.1 Gy or given within 4.5 weeks) was analyzed in relationship to tumor volume. Results: The volume of GTV-T and p16-status were found to be the strongest prognostic markers for LF, PFS and OS. For p16-positive tumors, an increase in tumor volume had a significantly higher negative prognostic impact compared with p16-negative tumors. Within a T-classification, patients with a smaller tumor, compared with a larger tumor, had a better prognosis. The importance of tumor volume remained after adjusting for nodal status, age, performance status, smoking status, sex, and hemoglobin-level. The adjusted hazard ratio for OS per cm3 increase in tumor volume was 2.3% (95% CI 0–4.9) for p16-positive and 1.3% (95% 0.3–2.2) for p16-negative. Exploratory analyses suggested that intensified RT could mitigate the negative impact of a large tumor volume. Conclusions: Outcome for patients with OPSCC treated with RT is largely determined by tumor volume, even when adjusting for other established prognostic factors. Tumor volume is significantly more influential for patients with p16-positive tumors. Patients with large tumor volumes might benefit by intensified RT to improve survival.
- Open Access
- 1 July 2021
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 50 (7) , 851-856
Mandibulotomy access to tumour sites: fewer complications for postoperative compared with preoperative radiotherapy
- 1 July 2021
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 50 (7) , 851-856
Open AccessMandibulotomy access to tumour sites: fewer complications for postoperative compared with preoperative radiotherapy